Breaking News Instant updates and real-time market news.

BA

Boeing

$199.08

2.64 (1.34%)

, GE

General Electric

$28.80

-0.2 (-0.69%)

16:20
06/19/17
06/19
16:20
06/19/17
16:20

On The Fly: Top stock stories for Monday

Stocks opened sharply higher and added to their early gains throughout the day. The Nasdaq was the clear winner as the tech sector rebounded from last week's selloff. Oil prices began the day in positive territory and pushed above $45 a barrel early in the day, but from there the sellers took over and pushed the commodity to a daily loss and back near $44 a barrel. ECONOMIC EVENTS: In the U.S., the economic calendar was quiet. In Europe, Emmanuel Macron's party secured a solid majority in the French parliament, although this was largely expected. Also, the the U.K. and EU commenced formal Brexit negotiations. COMPANY NEWS: Boeing (BA) kicked off the Paris Air Show with a number of announcements, including several new orders and the official launch of the 737 MAX 10 aircraft. Also as part of the start of that event, GE Capital Aviation Services (GE) and Caisse de depot et placement du Quebec announced that they have signed a commitment letter to create a $2B global aircraft financing platform, to be named Einn Volant Aircraft Leasing... EQT Corporation (EQT) announced an agreement to acquire Rice Energy (RICE) for total consideration of approximately $6.7B in cash and stock. EQT will also assume or refinance approximately $1.5B of net debt and preferred equity. After the deal news, EQT shares fell about 9% while Rice shares jumped 25%. MAJOR MOVERS: Among the notable gainers was Novadaq Technologies (NVDQ), which surged $5.70, or 95%, to $11.70 after the company agreed to be acquired by Stryker (SYK) for $11.75 per share in cash. Also higher was Clovis Oncology (CLVS), which gained 46.5% after the company announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib in certain ovarian cancer patients. Among the noteworthy losers was TripAdvisor (TRIP), which fell nearly 5% after Credit Suisse downgraded the stock to Underperform, its equivalent of a sell rating. Also lower were shares of Seattle Genetics (SGEN), which fell 4% after the company announced the discontinuation of the Phase III Cascade trial in acute myeloid leukemia. INDEXES: The Dow rose 144.71, or 0.68%, to 21,528.99, the Nasdaq gained 87.25, or 1.42%, to 6,239.01, and the S&P 500 advanced 20.31, or 0.83%, to 2,453.46.

BA

Boeing

$199.08

2.64 (1.34%)

GE

General Electric

$28.80

-0.2 (-0.69%)

EQT

EQT Corporation

$53.51

-5.26 (-8.95%)

RICE

Rice Energy

$24.57

4.88 (24.78%)

NVDQ

Novadaq

$11.70

5.7 (95.00%)

CLVS

Clovis

$87.88

27.91 (46.54%)

TRIP

TripAdvisor

$36.10

-1.81 (-4.77%)

SGEN

Seattle Genetics

$61.88

-2.64 (-4.09%)

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

  • 02

    Oct

BA Boeing
$199.08

2.64 (1.34%)

05/22/17
LEHM
05/22/17
NO CHANGE
Target $200
LEHM
Overweight
Boeing price target raised to $200 from $190 at Barclays
Barclays analyst Carter Copeland raised his price target for Boeing to $200 saying the company "possesses significant margin expansion potential" in the coming years. Investors are unwilling to believe in Boeing's margin expansion potential, Copeland tells investors in a research note. He keeps an Overweight rating on the shares.
05/10/17
COWN
05/10/17
NO CHANGE
COWN
Boeing 737 MAX engine issue likely very short-term and correctable, says Cowen
Cowen said the Boeing 737 MAX engine issue appears to be a very short-term "blip" and correctable. The firm's analyst doesn't think its a serious concern because Boeing still expects to deliver the first 737 MAX this month and the engine "problem" is not a design shortfall but what appears to be an easily fixable sub-tier supplier component problem.
05/09/17
UBSW
05/09/17
UPGRADE
Target $63
UBSW
Buy
Spirit AeroSystems upgraded to Buy from Neutral at UBS
UBS analyst David Strauss upgraded Spirit AeroSystems to Buy citing a favorable risk/reward following the recent pullback in the shares. The selloff reflects concerns around Spirit's pricing negotiations with Boeing (BA), Strauss tells investors in a research note. The analyst believes current share levels reflect a 35% decline in legacy 737/777 cash, which is well below his forecast. He his price target for Spirit AeroSystems remains $63.
06/05/17
SBSH
06/05/17
NO CHANGE
Target $70
SBSH
Buy
Citi sees path for Spirit AeroSystems hitting $85/share
Spirit AeroSystems (SPR) is trading near its all-time deepest earnings discount versus Boeing (BA) despite Spirit generating better financial results, Citi analyst Jason Gursky tells investors in a research note. While the protracted Boeing negotiation is an overhang, it is already reflected in the multiple, the analyst argues. He highlights Spirit's improving cash flow, balance sheet flexibility, shareholder-friendly cash deployment and new growth opportunities. He sees a path to $85 per share "over time" and reiterates a Buy rating on the shares with a one-year target of $70.
GE General Electric
$28.80

-0.2 (-0.69%)

06/01/17
FBCO
06/01/17
NO CHANGE
Target $34
FBCO
Outperform
General Electric has reached attractive entry point, says Credit Suisse
Credit Suisse analyst Julian Mitchell thinks the pendulum of investor sentiment regarding General Electric has swung too far in the negative direction, creating an attractive entry point into the stock. GE's organic growth seems underappreciated, argues Mitchell, who notes that its organic sales growth has topped most Electrical Equipment and Multi-Industry peers in recent years and into 2017. Meanwhile, GE's segments have shown "fairly healthy" operating leverage, added Mitchell, who has an Outperform rating and $34 price target on GE shares.
06/13/17
STFL
06/13/17
NO CHANGE
STFL
New General Electric CEO likely pleases investors, says Stifel
Stifel analyst Robert McCarthy says that investors were probably more pleased with GE's new CEO, John Flannery, than they would have been with either of the other two candidates- GE Power CEO Steve Bolze and CFO Jeff Bornstein. Flannery is viewed as more willing to make major changes than Bolze and is seen as not being as tied to the outgoing CEO as Bornstein, according to McCarthy. The analyst reiterates a $33 price target and a Buy rating on the stock.
05/25/17
DBAB
05/25/17
NO CHANGE
Target $24
DBAB
Sell
GE officially walked away from 2018 EPS target, says Deutsche Bank
Deutsche Bank analyst John Inch says General Electric CEO Jeff Immelt at a conference yesterday officially walked away from the company's $2.00-plus earnings per share framework for 2018 citing tougher markets. While investors had expected GE to abandon the $2.00-plus target, the company kept $2.00 per share at the high end of its 2018 framework, Inch tells investors in a research note. He believes $2.00 to be unrealistic, even as just a high point in the range. The analyst sees cash flow pressures continuing in 2018 and keeps a Sell rating on GE with a $24 price target.
05/31/17
DBAB
05/31/17
NO CHANGE
Target $24
DBAB
Sell
General Electric setting stage for dividend cut, says Deutsche Bank
Deutsche Bank analyst John Inch believes the stage is being set for General Electric to cut its common dividend. The analyst has a Sell rating on the shares with a $24 price target. Last Wednesday at a conference, GE provided a cash flow walk for the next two years that suggests it is likely to generate insufficient free cash flow to cover its common dividend this year, and barely enough next year, Inch tells investors in a research note. He believes a "reasonable dividend payout" on a future earnings reset could result in a GE dividend cut to 65c-75c. A dividend reduction could be part of an earnings "reset" lower and possibly in conjunction with eventual future leadership change, Inch writes.
EQT EQT Corporation
$53.51

-5.26 (-8.95%)

03/13/17
TUDR
03/13/17
UPGRADE
TUDR
Buy
EQT Corporation upgraded to Buy from Hold at Tudor Pickering
Tudor Pickering analyst Jeoffrey Lambujon upgraded EQT Corporation to Buy.
05/02/17
STFL
05/02/17
NO CHANGE
STFL
EQT Corporation weakness overdone, says Stifel
Stifel analyst Karl Chalabala says that the decline in EQT's stock following its Q2 results are overdone. Despite the company's lower than expected quarterly production guidance, the analyst raised his estimates, citing "higher well productivity from increased type curves and forward gas strips continuing to grind higher." He raised his price target on the stock to $81 from $63 and keeps a Buy rating on the shares.
03/23/17
STFL
03/23/17
INITIATION
STFL
Buy
EQT Corporation coverage resumed with a Buy at Stifel
Stifel analyst Karl J. Chalabala resumed coverage of EQT with a $63 price target and a Buy rating. The analyst says that the company has the highest leverage to coming natural gas price increases.
06/19/17
RBCM
06/19/17
NO CHANGE
RBCM
RBC says EQT deal positive for EQT Midstream, negative for Rice Midstream
After EQT (EQT) announced an agreement to acquire Rice Energy (RICE), RBC Capital analyst TJ Schultz called the news a positive for EQT Midstream (EQM) and EQT GP (EQGP), as it will enhance their growth outlook. However, he views it as a near-term negative for Rice Midstream (RMP), which now lacks clarity and no longer has drops to support growth. Schultz added that he thinks EQT eventually will look to collapse the midstream structure to eliminate the IDRs.
RICE Rice Energy
$24.57

4.88 (24.78%)

02/06/17
GHSC
02/06/17
UPGRADE
GHSC
Buy
Rice Energy upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Mike Kelly upgraded Rice Energy to Buy with a $28 price target citing compelling NAV upside and continued operational improvements.
03/31/17
GHSC
03/31/17
DOWNGRADE
Target $26
GHSC
Neutral
Rice Energy downgraded to Neutral from Buy at Seaport Global
Seaport Global analysts led by Mike Kelly downgraded Rice Energy to Neutral from Buy and and lowered its price target to $26 from $28. Kelly said Rice has limited upside relative to his $2.50/Mcf long-term gas estimate and valuation is inline with peers.
03/23/17
STFL
03/23/17
INITIATION
STFL
Buy
Rice Energy coverage resumed with a Buy at Stifel
Stifel analyst Karl J. Chalabala resumed coverage of Rice with a $32 price target and a Buy rating.
NVDQ Novadaq
$11.70

5.7 (95.00%)

06/01/17
STFL
06/01/17
NO CHANGE
STFL
Aetna may now cover Novadaq's DermACELL, says Stifel
06/19/17
WEDB
06/19/17
DOWNGRADE
WEDB
Neutral
Novadaq downgraded to Neutral from Outperform at Wedbush
Novadaq (NVDQ) is being acquired by Stryker (SYK) for $11.75 per share in cash.
03/01/17
FLTL
03/01/17
DOWNGRADE
FLTL
Hold
Novadaq downgraded to Hold from Buy at Feltl
Feltl downgraded Novadaq to Hold and lowered its price target to $7 from $8.75 citing increased uncertainty and lack of near-term catalysts following the Q4 report and guidance.
03/13/17
NORL
03/13/17
UPGRADE
Target $7
NORL
Market Perform
Novadaq upgraded to Market Perform from Underperform at Northland
Northland analyst Suraj Kalia upgraded Novadaq Technologies to Market Perform saying the stock is in "relative equilibrium." The analyst keeps a $7 price target for the shares.
CLVS Clovis
$87.88

27.91 (46.54%)

06/19/17
06/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Neutral from Sell at UBS with analyst Carter Gould saying he sees an improved risk/reward and a positive near-term setup going into the second quarter earnings call and strategic review. 2. Clovis (CLVS) upgraded to Neutral from Sell at Chardan. 3. Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Christopher Prykull saying early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. 4. Athene Holding (ATH) upgraded to Outperform from Neutral at Credit Suisse with analyst John Nadel saying he believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. 5. Credit Suisse (CS) upgraded to Buy from Hold at Deutsche Bank with analyst Kinner Lakhani saying an inflection in the company's operating results is near following the recent anticipated capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
COWN
06/19/17
NO CHANGE
Target $125
COWN
Market Perform
Tesaro price target cut to $125 from $145 at Cowen
Cowen analyst Boris Peaker reduced Tesaro's (TSRO) price target to $125 from $145 following Clovis' report this morning that rucaparib's pivotal ARIEL3 study met its PFS endpoint. The analyst said that all three leading PARPs are largely undifferentiated and trimmed niraparib peak rates across all subgroups. The analyst rates Tesaro shares a Market Perform.
06/19/17
JEFF
06/19/17
NO CHANGE
Target $124
JEFF
Hold
Tesaro worth $80 per share on fundamentals, says Jefferies
Jefferies analyst Eun Yang views Clovis Oncology's (CLVS) data today for rucaparib as "highly competitive" to Tesaro's (TSRO) niraparib. The data from Clovis will likely impact any potential takeover premium for Tesaro, Yang tells investors in a research note. The analyst views Tesaro as being worth $80 per share on a fundamental basis. She has a Hold rating and $124 price target on the shares. Tesaro in early trading is down 5%, or $7.09, to $137.22.
06/19/17
LEER
06/19/17
NO CHANGE
Target $114
LEER
Outperform
Clovis price target raised to $114 from $85 at Leerink
Leerink analyst Michael Schmidt raised his price target for Clovis Oncology (CLVS) to $114 following this morning's top-line Phase III Ariel3 results for Rubraca. The analyst views the data as "very compelling" when compared to competitor PARP inhibitors in ovarian cancer. He expects Rubraca to obtain a broad label in the second line ovarian cancer maintenance setting. As stated earlier today, Schmidt believes Clovis now represents a "prime takeout candidate." The analyst, however, notes that his new price target does not incorporate a takeout valuation. Schmidt keeps an Outperform rating on Clovis.
TRIP TripAdvisor
$36.10

-1.81 (-4.77%)

05/26/17
05/26/17
DOWNGRADE
Target $33

Underperform
TripAdvisor downgraded to Underperform on future competition at Macquarie
As previously reported, Macquarie downgraded TripAdvisor (TRIP) to Underperform from Neutral with a $33 price target, down from $52. Coverage was transferred to analyst Matthew Brooks who said the "best days" may be over for TripAdvisor and believes Google (GOOGL) is at the "top of the travel funnel." The analyst sees the future of travel search starting with travel queries addressed to AI assistants like Siri, or home devices like Amazon Echo, and expects TripAdvisor's hotel business economics to be more challenged in a world of voice and rationalization. Brooks said TripAdvisor's 500M reviews are largely text based and doesn't believe it has enough contextual information on reviewers to make the information relevant for users looking at the same travel product in the future.
06/19/17
06/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Costco (COST) downgraded to Hold from Buy at Deutsche Bank with analyst Paul Trussell saying positive pipeline catalysts have played out while competition is intensifying with Amazon.com (AMZN) and Wal-Mart (WMT) accelerating in-store and online efforts. The analyst lowered his price target for the shares to $172 from $187. 2. Kroger (KR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Vincent Sinisi saying there is increased structural margin risk within the Food Retail sector following Amazon's (AMZN) acquisition of Whole Foods (WFM) and said stocks are now appropriately pricing in flat medium-term growth. 3. Wayfair (W) downgraded to Hold from Buy at Maxim with analyst Tom Forte saying he views the current share price as fully reflecting its revenue growth opportunity over the next three years and his expectation that the company can meet the top-end of its long-term adjusted EBITDA margin target of 8%-10%. 4. Travelers (TRV) downgraded to Neutral from Buy at BofA/Merrill with analyst Jay Cohen citing valuation. 5. TripAdvisor (TRIP) downgraded to Underperform from Neutral at Credit Suisse with analyst Paul Bieber citing raised expectations for TV ad spending in 2018 paired with uncertainty regarding the return on TV advertising investment given the crowded ad market for online travel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
FBCO
06/19/17
DOWNGRADE
Target $34
FBCO
Underperform
TripAdvisor downgraded to Underperform from Neutral at Credit Suisse
Credit Suisse analyst Paul Bieber downgraded TripAdvisor (TRIP) to Underperform from Neutral citing raised expectations for TV ad spending in 2018 paired with uncertainty regarding the return on TV advertising investment given the crowded ad market for online travel. Also, the stock has a premium valuation despite inferior growth compared to Priceline (PCLN) and Expedia (EXPE), said Bieber, who lowered his price target on TripAdvisor to $34 from $40.
05/26/17
05/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral on balanced risk/reward at Buckingham with the firm citing more balanced risk/reward at current levels and raised its price target to $330 from $325. 2. JinkoSolar (JKS) was downgraded to Sell from Neutral at Citi and to Underweight from Overweight at Morgan Stanley. 3. Signet Jewelers (SIG) downgraded to Neutral from Buy at CL King with the firm citing lack of catalysts. 4. TripAdvisor (TRIP) downgraded to Underperform from Neutral at Macquarie with analyst Matthew Brooks saying the "best days" may be over for TripAdvisor and believes Google (GOOGL) is at the "top of the travel funnel." 5. Shire (SHPG) downgraded to Market Perform from Outperform at Bernstein with analyst Aaron Gal saying he believes risks to longer term earnings from competition and slowing Vyvanse sales are not being factored into consensus estimates. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SGEN Seattle Genetics
$61.88

-2.64 (-4.09%)

02/13/17
FBCO
02/13/17
NO CHANGE
Target $66
FBCO
Neutral
Seattle Genetics price target raised to $66 from $62 at Credit Suisse
Credit Suisse analyst Kennen MacKay raised his price target for Seattle Genetics to $66 from $62 saying he views the company's bid for Immunomedics' IMMU-132 positively. The analyst sees potential for near-term accelerated submission and potential approval in 2018 with potential for blockbuster sales. MacKay assumes a 60% probability of deal closing as Immunomedics has potential to seek additional bids. He reiterates a Neutral rating on Seattle Genetics' shares.
06/19/17
PIPR
06/19/17
NO CHANGE
Target $48
PIPR
Neutral
Seattle Genetics price target lowered to $48 from $57 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Seattle Genetics to $48 after the company announced the discontinuation of the Phase III Cascade trial in acute myeloid leukemia. The analyst views the news as a negative surprise and removed SGN-CD33A from his model. He keeps a Neutral rating on Seattle Genetics. The stock in early trading is down 9%, or $5.62, to $58.90.
03/15/17
OPCO
03/15/17
INITIATION
OPCO
Perform
Seattle Genetics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann initiated Seattle Genetics with a Perform rating, expecting Seattle Genetics will continue to develop its commercial drug, Adcetris, which is already approved for Hodgkin lymphoma.
05/05/17
05/05/17
UPGRADE

Outperform
Immunomedics upgraded at Wells Fargo after Seattle Genetics deal terminated
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Immunomedics (IMMU) to Outperform from Market Perform, stating that he is impressed at how quickly the new board moved to secure financing needed to advance IMMU132 and to put in place new management. With improved leadership, a better cash position and the Seattle Genetics (SGEN) deal terminated, Birchenough expects Immunomedics to secure "more appropriate" partnership terms for its "competitive asset for solid tumors," he tells investors. He increased his price target range for Immunomedics shares to $10-$11.50 from $5-$6.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.